Abstract
Abstract A family of novel warheads derived from dolastatins or auristatins were designed and synthesized. They showed similar or better antitumor activities against several typical cancer cell lines compared with dolastatin 10 or monomethylauristatin E or F. The conjugated ADCs with Trastuzumab have showed potent activities against Her2 breast cancer cell lines. The validated platform with novel cytotoxins can be potentially used to ADCs discovery and development. Citation Format: Shanghui Hu, Lucy X. Zhao, Xu Liu, Chao Li, Wei Hu, Zunrong Wang, Xufang Tian. Building a powerful ADCs discovery and development platform with novel dolastatin/auristatin payloads. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2646. doi:10.1158/1538-7445.AM2014-2646
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
